RxDoctor Payments Data

Sarabeth Martin, MD

Urology · Kalispell, MTNPI 1336466861

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (33.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Teleflex LLC at 33.6% of the total.

$3,636in general payments, 2019–2025

Across 49 payments — averaging $74.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$1K
  • Procept Biorobotics Corporation$1K
  • Astellas Pharma US Inc$423
  • Valencia Technologies Corporation$171
  • Medtronic$149
  • Johnson & Johnson$108
  • plus $392 from 7 others

What the payments were for

  • Speaking & faculty fees$1,22034%
  • Travel & lodging$1,01728%
  • Food & beverage$1,15332%
  • Education$2467%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,636 in reported general payments places this provider in the 75th percentile of 45 urology providers in Montana.

See all urology providers in Montana

Medicare billing

Part B allowed, 2024
$142,409
Medicare patients
420
Services billed
1,330

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron60$31,487
GemtesaVibegron31$15,512
Estradiol79$6,198
Mirabegron ErMirabegron11$4,448
Methenamine Hippurate52$2,495
Oxybutynin Chloride ErOxybutynin Chloride181$1,797
Testosterone17$1,308
Tamsulosin Hcl162$1,171
Cefdinir24$635
Fesoterodine Fumarate ErFesoterodine Fumarate18$632
Potassium Citrate ErPotassium Citrate18$617
Desmopressin Acetate24$535
Oxybutynin Chloride81$469
NitrofurantoinNitrofurantoin Macrocrystal22$332
Solifenacin Succinate15$296

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$423$31,48760 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 45 urology providers in Montana.

Other urology in Kalispell

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →